Charles Schwab Investment Management Inc. Has $8.07 Million Stock Position in Certara, Inc. (NASDAQ:CERT)

Charles Schwab Investment Management Inc. lifted its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 8.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 757,392 shares of the company's stock after purchasing an additional 57,817 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.47% of Certara worth $8,066,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Venturi Wealth Management LLC lifted its position in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares in the last quarter. KBC Group NV boosted its position in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after purchasing an additional 1,584 shares during the last quarter. GAMMA Investing LLC boosted its position in Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company's stock valued at $90,000 after purchasing an additional 6,868 shares during the last quarter. Finally, Moloney Securities Asset Management LLC purchased a new position in Certara in the fourth quarter valued at about $128,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Certara Stock Performance

NASDAQ:CERT traded down $0.03 during midday trading on Thursday, reaching $10.12. The stock had a trading volume of 1,101,564 shares, compared to its average volume of 1,016,418. The stock has a market capitalization of $1.63 billion, a P/E ratio of -50.60, a PEG ratio of 9.29 and a beta of 1.60. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm's fifty day simple moving average is $12.50 and its 200-day simple moving average is $11.46.

Analyst Ratings Changes

CERT has been the subject of several research reports. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target for the company. Barclays lifted their target price on shares of Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. William Blair restated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Finally, Stephens reaffirmed an "overweight" rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Certara has a consensus rating of "Moderate Buy" and an average target price of $15.83.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.